小米即将IPO 那些你不能错过的讯息

15th January, 2022
 

小米公司即将在港交所提交上市,有可能成为阿里巴巴之后,全球最大的科技企业IPO。

 

新加坡的投资者应该如何申请小米IPO ?

 

只需联系您的经纪人(broker),就能申请小米IPO。但是,投资者需要一次性申购新股至少20万新币。

 

如果您错过了小米IPO申请,不用担心,在小米上市交易的前一天,您还是可以通过辉立暗盘提前买入小米的股票。

 

暗盘交易介绍:

通常暗盘交易都是在新股上市的前一天,不过不是通过交易所的系统,而是通过券商内部的系统进行撮合报价。另外,并不是所有新股都有暗盘,只有在主板上市的新股才有暗盘,在创业板上市的股票,由于发行规则不同,参与的风险比较高,暂时没有接入暗盘交易。关于暗盘价和上市价的关系,尽管暗盘的涨跌从一定程度上体现了新股的受追捧程度,不过暗盘价并不能全面反映市场需求,买卖盘透明度不高,所以暗盘价并不能被视作该股的走势指标。

 

北京小米科技有限公司介绍

北京小米科技有限责任公司成立2010年4月,是一家专注于智能硬件和电子产品研发的移动互联网公司。小米还是继苹果、三星、华为之后第四家拥有手机芯片自研能力的科技公司。通过旗下生态链品牌MIJIA(米家),小米的产品线从智能手机及耳机、移动电源等周边产品,音箱、手环、电脑等相关移动智能硬件,扩展到电视、机顶盒、路由器、空气净化器、电饭煲等家居消费产品,截至2018年3月底,小米已进入全球74个国家和地区的市场,并在其中15个市场智能手机出货量名列前五。目前,小米已成为全球第四大智能手机厂商,2017年四季度手机销量全球排名仅次于苹果、三星、华为。

 

根据招股文件显示,小米计划将30% 通过IPO募集到的资金用于研发及开发智能手机、电视、笔记本电脑、人工智能音响等核心产品;30%用于扩大投资及强化生活消费品与移动互联网产业链;30%用于全球扩展;10%用作一般营运用途。

 

据小米招股书披露,小米2017年收入1146亿元,经营利润122.16亿元; 2016年收入684亿元,经营利润为37.85亿元;2015年收入668亿元,经营利润为13.73亿元。

 

截至2017年12月31日,小米集团有净负债人民币1,272亿元及累积亏损人民币1,290亿元,主要是由于可转换可赎回优先股产生大额公允价值亏损。

 

小米的营收分别为4个业务板块,分别是智能手机、IoT与生活消费产品、互联网服务及其他。其中,智能手机业务是其主要收入来源,2017年来自智能手机行业的收入为805.64亿元,占总收入的比例为70.3%;来自IoT与生活消费产品的营收为234.48亿元,占比为20.5%;来自互联网服务的营收为98.96亿元,占比为8.6%。

 

小米近期在加速线下扩张。资料显示,2018年1月13日,小米之家中国范围内门店数突破300家。小米之家在2017年共覆盖170座城市,新增235家门店,2家品牌店,共接待顾客6713万人次。2018年4月30日,小米之家宣布于4月28日-5月1日在中国多开设61家门店。

 

海外市场方面,小米2015年、2016年、2017年的海外市场收入分别为40.5亿元、91.5亿元、320.8亿元,2017年同比增长了250%。目前,小米已进入全球74个国家和地区。

 

2017年小米手机在印度、俄罗斯、新加坡、捷克等十几个国家进入了销量前五。

 

辉立暗盘交易细则

在香港,辉立证券是第一个为客户提供场外交易渠道的券商,交易时间一般为新股上市前一个交易日的下午4点15至下午6点半,半日市的交易时间为下午2点15至下午4点半。

 

个股举例  – 阅文集团

 

腾讯的子公司阅文与2017年11月8日赴港上市,引发投资者的认购热潮。该股发行价55港币,每手股数为200股,上市前超额认购达625倍。据辉立交易场资料显示,阅文暗盘开市报77.9元,之后高见92元,收报89.65元,较招股价上涨63%。

YUEWENJITUAN

上市首日,阅文开盘报价90港元,后迅速上涨,一度触及110港元,较发行价上涨100%,尽管随后涨幅小幅回落,但一直保持在100港币之上,最后收盘报价102.4港元,上涨近86%,总市值达928亿港元。

 

个股举例  – 希玛眼科
顶着马化腾概念股光环的希玛眼科于2018年1月15日在港交所挂牌。希玛眼科欲募资7300万美元,其中10%的认购者为散户。最终以高达1500倍的超额认购,超越阅文的620倍超额认购。希玛眼科招股书显示,此次IPO将发售1.97亿股股份,其中香港发售1970万股,国际发售1.773亿股,发售股份将占公司全球发售完成后的已发行股本的25.05%,价格在2.35-2.9港元之间,每手2000股。

XIMAYANKE
在创下史上最高超额认购记录后,前一交易日的暗盘交易也极为火爆。根据辉立证券香港官网数据显示,希玛眼科交易价达4.97港元,较招股价大涨71%。总成交额超过1.2亿港元。

 

上市当日,该股开盘即暴涨84.5%,报5.35港元。之后股价如坐火箭一般飙升,连续4日大幅上涨,最高价达19.9港元,较发行价涨686.2%,较第一天开盘价涨371.96%。之后有所回落。

 

 

关键字:新加坡股票研报,新加坡股,新加坡研报,新加坡房地产, 新加坡账户,交易新加坡股票,新加坡股票开户,免费开户,在线开设新加坡股票开户,新加坡证券,新加坡券商,投资组合,IPO, 香港IPO, 小米IPO

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com